Fresh and cumulative live birth rates in mild versus conventional stimulation for IVF cycles in poor ovarian responders: a systematic review and meta-analysis
- PMID: 33614987
- PMCID: PMC7882043
- DOI: 10.1093/hropen/hoaa066
Fresh and cumulative live birth rates in mild versus conventional stimulation for IVF cycles in poor ovarian responders: a systematic review and meta-analysis
Erratum in
-
Correction to: Fresh and cumulative live birth rates in mild versus conventional stimulation for IVF cycles in poor ovarian responders: a systematic review and meta-analysis.Hum Reprod Open. 2024 Jul 3;2024(3):hoae044. doi: 10.1093/hropen/hoae044. eCollection 2024. Hum Reprod Open. 2024. PMID: 38974323 Free PMC article.
Abstract
Study question: Are cumulative and live birth rates (LBRs) comparable in poor ovarian response women treated with different protocols of mild stimulation IVF (i.e. oral compounds, lower doses or shorter treatments) versus conventional IVF?
Summary answer: Mild ovarian stimulation (MOS) results in comparable outcomes to those of conventional stimulation in poor ovarian response patients with low ovarian reserve.
What is known already: Several randomized trials and meta-analyses have been published evaluating the role of mild (MOS) versus conventional ovarian stimulation in poor ovarian response patients. Most report a potentially higher safety profile, patient satisfaction and lower costs, suggesting that the higher cycle cancellation rate and fewer oocytes retrieved following MOS does not affect the final reproductive outcome. Additionally, over the last few years, new publications have added data regarding MOS, and shown the possible benefit of a higher oocyte yield which may also improve prognosis in patients with poor ovarian response.
Study design size duration: We conducted a systematic search of relevant randomized controlled trials (RCTs). We searched electronic databases, including MEDLINE, EMBASE, LILACS-BIREME, CINAHL, The Cochrane Library, CENTRAL (Cochrane Register), Web of Science, Scopus, Trip Database and Open Grey, to identify all relevant studies published up to March 2020. We examined trial registries for ongoing trials. No publication-year or language restrictions were adopted. We explored the reference list of all included studies, reviews and abstracts of major scientific meetings. The primary outcomes were cumulative and fresh LBR (CLBR and FLBR) per woman randomized.
Participants/materials setting methods: We included subfertile women undergoing IVF/ICSI characterized as poor responders and compared primary and secondary outcomes between the different protocols of mild stimulation IVF (i.e. oral compounds, lower doses or shorter treatments) and conventional IVF. We used the PICO (Patients, Intervention, Comparison and Outcomes) model to select our study population.
Main results and the role of chance: Overall, 15 RCTs were included in the meta-analysis. CLBR and FLBR were comparable between mild versus conventional stimulation (RR 1.15; 95% CI: 0.73 - 1.81; I2 = 0%, n = 424, moderate certainty and RR 1.01; 95% CI: 0.97 - 1.04; I 2 = 0%, n = 1001, low certainty, respectively). No difference was observed either when utilizing oral compounds (i.e. letrozole and clomiphene) or lower doses. Similarly, ongoing pregnancy rate (OPR) and clinical pregnancy rate (CPR) were equivalent when comparing the two groups (RR 1.01; 95% CI: 0.98 - 1.05; I 2 = 0%, n = 1480, low certainty, and RR 1.00; 95% CI: 0.97 - 1.03; I2 = 0%, n = 2355, low certainty, respectively). A significantly lower oocyte yield (mean differences (MD) -0.80; 95% CI: -1.28, -0.32; I2 = 83%, n = 2516, very low certainty) and higher rate of cycle cancellation (RR 1.48; 95% CI: 1.08 - 2.02; I2 = 62%, n = 2588, low certainty) was observed in the MOS group.
Limitations reasons for caution: The overall quality of the included studies was low to moderate. Even though strict inclusion criteria were used, the selected studies were heterogeneous in population characteristics and treatment protocols. We found no differences in CLBR between MOS and COS (95% CI: 0.73 - 1.81.).
Wider implications of the findings: MOS could be considered as a treatment option in low prognosis poor responder patients, given that it results in similar fresh and CLBRs compared with COS. A milder approach is associated with a lower number of oocytes retrieved and a higher cancellation rate, although treatment cost is significantly reduced. Future research should focus on which type of ovarian stimulation may be of benefit in better prognosis women.
Study funding/competing interests: There were no sources of financial support. N.P.P. received research grants, honoraria for lectures from: Merck Serono, MSD, Ferring Pharmaceuticals, Besins International, Roche Diagnostics, IBSA, Theramex and Gedeon Richter. P.D. received unrestricted grants and honoraria from Merck Serono, MSD and Ferring Pharmaceuticals. I.G.F. received unrestricted grants and honoraria from Merck Serono, MSD, Ferring Pharmaceuticals, Gedeon-Richter and IBSA. P.M.B. reported no conflict of interest.
Trial registration number: CRD42020167260.
Keywords: conventional stimulation; meta-analysis; mild stimulation; poor ovarian response; systematic review.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.
Figures




Similar articles
-
The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF.Hum Reprod. 2023 May 2;38(5):927-937. doi: 10.1093/humrep/dead038. Hum Reprod. 2023. PMID: 36864699 Free PMC article. Clinical Trial.
-
One-year cumulative live birth rate associated with the number of oocytes in ovarian stimulation with follitropin delta: a pooled analysis of four randomized controlled trials.Hum Reprod. 2025 Aug 1;40(8):1526-1534. doi: 10.1093/humrep/deaf111. Hum Reprod. 2025. PMID: 40505136 Free PMC article.
-
ESHRE guideline: ovarian stimulation for IVF/ICSI†.Hum Reprod Open. 2020 May 1;2020(2):hoaa009. doi: 10.1093/hropen/hoaa009. eCollection 2020. Hum Reprod Open. 2020. PMID: 32395637 Free PMC article.
-
No additional risk of congenital anomalies after first-trimester dydrogesterone use: a systematic review and meta-analysis.Hum Reprod Open. 2024 Jan 23;2024(1):hoae004. doi: 10.1093/hropen/hoae004. eCollection 2024. Hum Reprod Open. 2024. PMID: 38344249 Free PMC article. Review.
-
Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis.Hum Reprod. 2022 May 3;37(5):954-968. doi: 10.1093/humrep/deac035. Hum Reprod. 2022. PMID: 35220429 Free PMC article.
Cited by
-
Ultra-low-dose and very-low-dose Lupron downregulation protocols for poor responders based on POSEIDON group 3 and 4 classifications.J Assist Reprod Genet. 2023 Aug;40(8):1881-1895. doi: 10.1007/s10815-023-02842-8. Epub 2023 Jun 16. J Assist Reprod Genet. 2023. PMID: 37326893 Free PMC article.
-
Cumulative live birth rate in mild versus conventional stimulation in progestin-primed ovarian stimulation protocols for individuals with low prognosis.Front Endocrinol (Lausanne). 2023 Nov 14;14:1249625. doi: 10.3389/fendo.2023.1249625. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38033995 Free PMC article.
-
Omega-3 fatty acids and L-carnitine prevent meiotic oocyte damage induced by follicular fluid from infertile women with endometriosis: an experimental study.JBRA Assist Reprod. 2023 Sep 28;27(4):610-8. doi: 10.5935/1518-0557.20230023. Online ahead of print. JBRA Assist Reprod. 2023. PMID: 37768816 Free PMC article.
-
Intraovarian PRP injection improves oocyte quality and early embryo development in mouse models of chemotherapy-induced diminished ovarian reserve.Aging (Albany NY). 2024 Sep 13;16(17):12123-12137. doi: 10.18632/aging.206099. Epub 2024 Sep 13. Aging (Albany NY). 2024. PMID: 39276378 Free PMC article.
-
The cumulative live birth rates of 18 593 women with progestin-primed ovarian stimulation-related protocols and frozen-thawed transfer cycles.Hum Reprod Open. 2023 Dec 21;2024(1):hoad051. doi: 10.1093/hropen/hoad051. eCollection 2024. Hum Reprod Open. 2023. PMID: 38188854 Free PMC article.
References
-
- Abdel Mohsen I, Ezz El Din R.. Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI. Gynecol Endocrinol 2013;29:105–108. - PubMed
-
- Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, Fischer R, Galliano D, Polyzos NP, Sunkara SK. et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril 2016;105:1452–1453. - PubMed
-
- Baart EB, Martini E, Eijkemans MJ, Van Opstal D, Beckers NG, Verhoeff A, Macklon NS, Fauser BC.. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod 2007;22:980–988. - PubMed
-
- Bastu E, Buyru F, Ozsurmeli M, Demiral I, Dogan M, Yeh J.. A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. Eur J Obstet Gynecol Reprod Biol 2016;203:30–34. - PubMed
-
- Berkkanoglu M, Ozgur K.. What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders? Fertil Steril 2010;94:662–665. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials